Quantitative analysis revealed that CRC patients with high ARL4C expression were significantly more likely to experience recurrence (61.3% vs. 18.7%) and metastasis (17.5% vs. 3.1%) than those with low ARL4C expression following oxaliplatin-based therapy (Figure 9H-I). This evidence concerns the gene ARL4C and colorectal carcinoma.